CSPC Pharmaceutical receives US$15 million milestone payment under Corbus license deal
CRBP•CSPC Megalith received a US$15 million development milestone payment from Corbus Pharmaceuticals on November 18, 2026. Total upfront and development milestone payments under the license agreement reached US$32.5 million.
1. Milestone payment
CSPC Pharmaceutical Group subsidiary CSPC Megalith received a US$15 million development milestone payment from Corbus Pharmaceuticals on November 18, 2026. The exclusive license agreement gives Corbus development and commercialization rights to CRB-701 (SYS6002), an antibody-drug conjugate targeting Nectin-4.




